

BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE REVENUES
QUARTERLY REVENUES TREND ANALYSIS
(Unaudited, dollars in millions)

	2020							2021							\$ Change		% Change	
	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr	Year	1st Qtr	2nd Qtr	6 Months	3rd Qtr	9 Months	4th Qtr	Year	Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
Prioritized Brands																		
Revlimid	\$ 2,915	\$ 2,884	\$ 5,799	\$ 3,027	\$ 8,826	\$ 3,280	\$ 12,106	\$ 2,944	\$ 3,202	\$ 6,146	\$ 3,347	\$ 9,493			\$ 320	\$ 667	11%	8%
Eliquis	2,641	2,163	4,804	2,095	6,899	2,269	9,168	2,886	2,792	5,678	2,413	8,091			318	1,192	15%	17%
Opdivo	1,766	1,653	3,419	1,780	5,199	1,793	6,992	1,720	1,910	3,630	1,905	5,535			125	336	7%	6%
Orencia	714	750	1,464	826	2,290	867	3,157	758	814	1,572	870	2,442			44	152	5%	7%
Pomalyst/Imnovid	713	745	1,458	777	2,235	835	3,070	773	854	1,627	851	2,478			74	243	10%	11%
Sprycel	521	511	1,032	544	1,576	564	2,140	470	541	1,011	551	1,562			7	(14)	1%	(1)%
Yervoy	396	369	765	446	1,211	471	1,682	456	510	966	515	1,481			69	270	15%	22%
Abraxane	300	308	608	342	950	297	1,247	314	296	610	266	876			(76)	(74)	(22)%	(8)%
Empliciti	97	97	194	96	290	91	381	85	86	171	82	253			(14)	(37)	(15)%	(13)%
Reblozyl	8	55	63	96	159	115	274	112	128	240	160	400			64	241	67%	**
Inrebic	12	15	27	13	40	15	55	16	16	32	22	54			9	14	69%	35%
Onureg	—	—	—	3	3	14	17	15	12	27	21	48			18	45	**	**
Zeposia	—	1	1	2	3	9	12	18	28	46	40	86			38	83	**	**
Breyanzi	—	—	—	—	—	—	—	—	17	17	30	47			30	47	N/A	N/A
Abecma	—	—	—	—	—	—	—	—	24	24	71	95			71	95	N/A	N/A
Established Brands																		
Vidaza	158	126	284	106	390	65	455	54	45	99	36	135			(70)	(255)	(66)%	(65)%
Baraclude	122	121	243	100	343	104	447	113	109	222	105	327			5	(16)	5%	(5)%
Other Brands ^(a)	418	331	749	287	1,036	279	1,315	339	319	658	339	997			52	(39)	18%	(4)%
Total	\$ 10,781	\$ 10,129	\$ 20,910	\$ 10,540	\$ 31,450	\$ 11,068	\$ 42,518	\$ 11,073	\$ 11,703	\$ 22,776	\$ 11,624	\$ 34,400			\$ 1,084	\$ 2,950	10%	9%

** In excess of +/- 100%.

(a) Includes products that have lost exclusivity in major markets, over-the-counter (OTC) brands and royalty revenue.